Article: Oral mucosal fungal infections

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleOral mucosal fungal infections
AuthorsSamaranayake, LP
Keung Leung, W
Jin, L
Issue Date2009
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PRD
CitationPeriodontology 2000, 2009, v. 49 n. 1, p. 39-59 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1600-0757.2008.00291.x
AbstractThis review has provided an overview of variants of oral mucosal candidiasis and current therapeutic techniques followed by an outline of the rare oral mycoses and their management. The advent of the HIV infection and the increasing prevalence of compromised individuals in the community as a consequence of surgical and medical advances have resulted in a resurgence of opportunistic infections, including oral candidiasis and other rare mycoses that were once considered exotic. It is now recognized that oral candidiasis may present in many clinical guises, including the classic white lesion of thrush as well in as nondescript, red mucosal lesions that may confound the unwary clinician. Other mycotic diseases, such as aspergillosis, cryptococcosis, histoplasmosis and mucormycosis, may manifest intra-orally, both as primary lesions and as secondary manifestations of systemic disease. Periodontal manifestations of mycotic diseases are rare. If at all, such lesions may present as erythematous areas as in linear gingival erythema and rarely as ulcerations in exotic mycoses. Most of the oral mycoses respond well to either topical or systemic therapy with the polyenes or azoles. In general, the management of oral fungal infections has been revolutionized by the triazole group of drugs, fluconazole and itraconazole, although recent reports indicate an alarming increase of resistant organisms, in particular to fluconazole. © 2009 Blackwell Munksgaard.
ISSN0906-6713
2011 Impact Factor: 3.961
2011 SCImago Journal Rankings: 0.202
DOIhttp://dx.doi.org/10.1111/j.1600-0757.2008.00291.x
ISI Accession Number IDWOS:000261838700003
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorSamaranayake, LP
dc.contributor.authorKeung Leung, W
dc.contributor.authorJin, L
dc.date.accessioned2010-05-31T03:23:55Z
dc.date.available2010-05-31T03:23:55Z
dc.date.issued2009
dc.description.abstractThis review has provided an overview of variants of oral mucosal candidiasis and current therapeutic techniques followed by an outline of the rare oral mycoses and their management. The advent of the HIV infection and the increasing prevalence of compromised individuals in the community as a consequence of surgical and medical advances have resulted in a resurgence of opportunistic infections, including oral candidiasis and other rare mycoses that were once considered exotic. It is now recognized that oral candidiasis may present in many clinical guises, including the classic white lesion of thrush as well in as nondescript, red mucosal lesions that may confound the unwary clinician. Other mycotic diseases, such as aspergillosis, cryptococcosis, histoplasmosis and mucormycosis, may manifest intra-orally, both as primary lesions and as secondary manifestations of systemic disease. Periodontal manifestations of mycotic diseases are rare. If at all, such lesions may present as erythematous areas as in linear gingival erythema and rarely as ulcerations in exotic mycoses. Most of the oral mycoses respond well to either topical or systemic therapy with the polyenes or azoles. In general, the management of oral fungal infections has been revolutionized by the triazole group of drugs, fluconazole and itraconazole, although recent reports indicate an alarming increase of resistant organisms, in particular to fluconazole. © 2009 Blackwell Munksgaard.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationPeriodontology 2000, 2009, v. 49 n. 1, p. 39-59 [How to Cite?]
DOI: http://dx.doi.org/10.1111/j.1600-0757.2008.00291.x
dc.identifier.citeulike3821160
dc.identifier.doihttp://dx.doi.org/10.1111/j.1600-0757.2008.00291.x
dc.identifier.epage59
dc.identifier.hkuros154199
dc.identifier.isiWOS:000261838700003
dc.identifier.issn0906-6713
2011 Impact Factor: 3.961
2011 SCImago Journal Rankings: 0.202
dc.identifier.issue1
dc.identifier.openurl
dc.identifier.pmid19152525
dc.identifier.scopuseid_2-s2.0-57849103561
dc.identifier.spage39
dc.identifier.urihttp://hdl.handle.net/10722/58107
dc.identifier.volume49
dc.languageeng
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/PRD
dc.publisher.placeDenmark
dc.relation.ispartofPeriodontology 2000
dc.relation.referencesReferences in Scopus
dc.subject.meshAntifungal Agents - therapeutic use
dc.subject.meshCandidiasis, Oral - complications - drug therapy - microbiology - pathology
dc.subject.meshDenture, Complete, Upper - adverse effects
dc.subject.meshHIV Infections - complications
dc.subject.meshHumans
dc.subject.meshMouth Mucosa - microbiology
dc.subject.meshMycoses - drug therapy - microbiology - pathology
dc.titleOral mucosal fungal infections
dc.typeArticle